Comprender la promociÃ³n farmacÃ©utica y responder a ella - Multiple ...

More documents

Recommendations

Info

110 | Comprender la promoción farmacéutica y responder a ella - una guía prácticaReferenciasAikin KJ, Swasy JL, Braman AC (2004). Patient and physician attitudes and behaviors associated with DTCpromotion of prescription drugs – summary of FDA survey research results. US Dept of Health and Human Services,Food and Drug Administration. Center for Drug Evaluation and Research. 19 November (Disponible en:http://www.fda.gov/cder/ddmac/Final%20Report/FRFinalExSu1119042.pdf, se tuvo acceso el 17 de abril de 2009).Anón. (2005). L’année 2004 du médicament: Innovation en panne et prises de risques. La revue Prescrire, 258:139-148.Arnold M (2005). Changing channels. Medical Marketing and Media, 40(4):34-39.Australian Government. Department of Foreign Affairs and Trade (2006). Australia-United States Free TradeAgreement. Annex 2-C Pharmaceuticals.Basara LR (1996). The impact of a direct-to-consumer prescription medication advertising campaign on newprescription volume. Drug Information Journal; 30(3):715-729.Bell RA, Wilkes MS, Kravitz RL (2000). The educational value of consumer-targeted prescription drug printadvertising. Journal of Family Practice, 49(12):1092-1098.Bombardier C, Laine L, Reicin A et al. (2000). For the VIGOR Study Group. Comparison of upper gastrointestinaltoxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine;343:1520-1528.Britten N, Ukoumunne O (1997). The influence of patients’ hopes of receiving a prescription on doctors’ perceptionsand the decision to prescribe: a questionnaire survey. British Medical Journal, 315:1506-1510.Brown H (2007). Sweetening the pill. British Medical Journal, Mar; 334:664-666.Cockburn J, Pit S (1997). Prescribing behaviour in clinical practice: Patients’ expectations and doctors’ perceptionsof patients’ expectations – a questionnaire study. British Medical Journal, 315:520-523.Epstein RM, Shields CG, Franks P et al. (2007). Exploring and validating patient concerns: relation to prescribingfor depression. Annals of Family Medicine, 5:21-28.Findlay S (2001). Prescription drugs and mass media advertising. Washington D.C., National Institute of HealthCare Management. Septiembre (Disponible en: http://www.nihcm.org/publications/prescription_drugs, se tuvoacceso el 17 de abril de 2009).Frosch DL, Krueger PM, Hornik RC et al. (2007). Creating demand for prescription drugs: a content analysis oftelevision direct-to-consumer advertising. Annals of Family Medicine, 5:6-13.Graham DJ, Campen D, Hui R et al. (2005). Risk of acute myocardial infarction and sudden cardiac death inpatients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nestedcase-control study. Lancet, 365:475-481.Hansen RA. Schommer JC, Cline RR et al. (2005).The association of consumer cost-sharing and direct-to-consumeradvertising with prescription drugs. Research in Social and Administrative Pharmacy, 1:139-157.Heinrich J (2002). US Prescription Drugs. FDA Oversight of direct-to-consumer advertising has limitations. Reportto Congressional Requesters. US General Accounting Office. GAO-03-177. Octubre.Iizuka T, Zhe Jin G (2005). Drug advertising and health habit. National Bureau of Economic Research WorkingPaper Series 11770 (Available at: http://www.nber.org/papers/w11770, se tuvo acceso el 17 de abril de 2009)..’t Jong GW, Stricker BHC, Sturkenboom MCJM (2004). Marketing in the lay media and prescriptions of terbinafinein primary care: Dutch cohort study. British Medical Journal, 328:931.
Capítulo 5 - Promoción a los consumidores: Cómo responder a los pacientes que solicitan medicamentos promocionados | 111Kravitz RL, Epstein RM, Feldman MD et al. (2005). Influence of patients’ requests for direct-to-consumer advertisedantidepressants: a randomised controlled trial. Journal of the American Medical Association, 293:1995-2002.Lasser KE, Allen PD, Woolhandler SJ et al. (2002). Timing of new black box warnings and withdrawals forprescription medications. Journal of the American Medical Association, 287:2215-20.Marinac JS, Godfrey LA, Buchinger C et al. (2004). Attitudes of older Americans toward direct-to-consumeradvertising: predictors of impact. Drug Information Journal. 38(3):301-311.Mintzes B (1998). Blurring the boundaries: new trends in drug promotion. Health Action International (HAI-Europe), Amsterdam (Available at: http://www.haiweb.org, se tuvo acceso el 17 de abril de 2009).Mintzes B, Barer ML, Kravitz RL et al. (2003). How does direct-to-consumer advertising (DTCA) affect prescribing?A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal,169:405-412.Moynihan R, Heath I, Henry D (2002). Selling sickness: the pharmaceutical industry and disease-mongering. BritishMedical Journal, 324:886-891.Public Citizen Health Research Group (2003). Do not use! Rosuvastatin (Crestor) - a new but more dangerouscholesterol lowering 'statin' drug. Worst Pills Best Pills Newsletter, Octubre 2003 (Disponible en:http://www.worstpills.org/public/crestor.cfm, se tuvo acceso el 17 de abril de 2009).Quick J, Hogerzeil HV, Rágo L et al. (2003). Ensuring ethical drug promotion – whose responsibility? Lancet,362:747.Salpeter SR, Buckley NS, Ormiston TM et al. (2006). Meta-analysis: Effect of long-acting beta-agonists on severeasthma exacerbations and asthma-related deaths. Annals of Internal Medicine, 144:904-12.Therapeutics Initiative (2002). Do single stereoisomer drugs provide value? Therapeutics Letter 45; junio-septiembr2002 (Disponible en: http://www.ti.ubc.ca/pages/letter45.htm, se tuvo acceso el 17 de abril de 2009).Toop L, Richards D, Dowell T et al. (2003). Direct-to-consumer advertising of prescription drugs in New Zealand:For health or for profit. Report to the Minister of Health supporting the case for a ban on DTCA. Christchurch,University of Otago, febrero de 2003.Topol EJ (2004). Failing the public health – rofecoxib, Merck and the FDA. New England Journal of Medicine,351:1707-1709.US Food and Drug Administration (2005). CDER. Patient Information Sheet Vardenafil hydrochloride (marketedas Levitra) (Disponible en: http://www.fda.gov/cder/drug/InfoSheets/patient/vardenafilPIS.htm, se tuvo acceso el17 de abril de 2009).US Food and Drug Administration (2007). FDA Public Health Advisory. Tegaserod maleate (marketed as Zelnorm).Marzo 30 (Disponible en: http://www.fda.gov/cder/drug/advisory/tegaserod.htm, se tuvo acceso el 17 de abril de2009).Warshaw E, Fett DD, Bloomfield H et al. (2005). Pulse versus continuous terbinafine for onychomycosis: Arandomized, double-blind, controlled trial. Journal of the American Academy of Dermatology, 53(4):578-584.Woloshin S, Schwartz LM, Tremmel J et al. (2001). Direct-to-consumer advertisements for prescription drugs:what are Americans being sold? Lancet, 358:1141-46.World Health Organization (1988). Ethical criteria for medicinal drug promotion. Ginebra, WHO. (Existe versiónen español: Criterios Éticos para la Promoción de Medicamentos. Ginebra, OMS, 1988).
Page 3 and 4:
XXXXXComprenderla promoción farmac
Page 5:
ContenidoPrefacio .................
Page 9 and 10:
Reconocimientos | 5ReconocimientosA
Page 11 and 12:
Reconocimientos | 7Traductores:Al r
Page 13 and 14:
Siglas y acrónimos | 9Siglas y acr
Page 15 and 16:
Capítulo 1 - La promoción farmac
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Capítulo 2 - Técnicas que influye
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Capítulo 3 - Análisis de los anun
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Referencias en los anunciosCapítul
Page 59 and 60:
Page 61 and 62:
Page 63 and 64: Capítulo 3 - Análisis de los anun
Page 69 and 70: Capítulo 4 - Los visitadores médi
Page 91 and 92: Capítulo 5 - Promoción a los cons
Page 113: Capítulo 5 - Promoción a los cons
Page 117 and 118: Capítulo 6 - Aprender a no bailar
Page 137 and 138: Capítulo 7Capítulo 7 - La regulac
Page 139 and 140: Capítulo 7 - La regulación de la
Page 163 and 164: Capítulo 8 - Usar información imp
Page 165 and 166:
Capítulo 8 - Usar información imp
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Capítulo 9Capítulo 9 - La promoci
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 196:
El papel de médicos y farmacéutic
show all

Comprender la promociÃ³n farmacÃ©utica y responder a ella - Multiple ...

Create successful ePaper yourself

Delete template?

Save as template?